Overview

A Study of HLX42 in Advanced/Metastatic Solid Tumors

Status:
RECRUITING
Trial end date:
2027-06-14
Target enrollment:
Participant gender:
Summary
This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX42.
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai Henlius Biotech